ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis - Part 2 - Diagnostic Criteria and Appropriate Utilization

Oct 2, 2026

Uploaded by dbqoiu

Cardiac amyloidosis is an increasingly recognized but often underdiagnosed cause of heart failure and mortality, and growing evidence supports noninvasive diagnosis. This Part 2 consensus, authored by an international panel representing multiple societies, addresses the lack of standardized diagnostic criteria and imaging utilization practices. It defines diagnostic criteria for cardiac amyloidosis and provides appropriate-use guidance for echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in patients with known or suspected disease.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

INTRODUCTION

Key goals of Part 2

Diagnostic criteria and imaging utilization

Multimodality modalities covered

Writing group and endorsements

ASNC EXPERT CONSENSUS RECOMMENDATIONS ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 2 OF 2—DIAGNOSTIC CRITERIA AND APPROPRIATE UTILIZATION Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies deﬁne the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis. Key Words: Cardiac amyloidosis Æ Diagnosis Æ Appropriate use Æ Expert consensus Æ Multimodality | Abbreviations
AL Amyloid immunoglobulin light chains
ATTR Amyloid transthyretin
DPD 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid
EF Ejection fraction | HMDP Hydroxymethylenediphosphonate
LV Left ventricular
PYP Pyrophosphate
Tc 99mTechnetium | | --- | --- | This article is being jointly published in the Journal of Nuclear Cardiology, Journal of Cardiac Failure, and Circulation: Cardiovascular Imaging. Part 1 – Evidence Base and Standardized Methods of Imaging is available at [https://doi.org/10.1007/s12350-019-01760-6](https://doi.org/10.1007/s12350-019-01760-6) . This document was approved for publication by the governing body of the American Society of Nuclear Cardiology (ASNC) and was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), American Society of Echocardiography (ASE), the European Association of Nuclear Medicine (EANM), the Heart Failure Society of America (HFSA), the International Society of Amyloidosis (ISA), the Society for Cardiovascular Magnetic Resonance (SCMR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) . Reprint requests: Sharmila Dorbala, MD, MPH, FASNC (Chair), Cardiac Amyloidosis Program, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; [sdorbala@bwh.harvard.edu](sdorbala@bwh.harvard.edu)[ ](sdorbala@bwh.harvard.edu)[J Nucl Cardiol 2020](J Nucl Cardiol 2020);[27:659](27:659)–[73](73). 1071-3581/$34.00 Copyright 􀀂 2019 American Society of Nuclear Cardiology, Heart Failure Society of America, and American Heart Association. doi:10.1007/s12350-019-01761-5 660 Expert Consensus Recommendations Journal of Nuclear Cardiology􀀃 Multimodality Imaging in Cardiac Amyloidosis March/April 2020 | Writing Group Members | | --- | | Sharmila Dorbala, MD, MPH, FASNC (Chair)a
Yukio Ando, MD, PhDb Sabahat Bokhari, MDc Angela Dispenzieri, MDd Rodney H. Falk, MDa Victor A. Ferrari, MDe Marianna Fontana, PhDf Olivier Gheysens, MD, PhDg Julian D. Gillmore, MD, PhDf
Andor W.J.M. Glaudemans, MD, PhDh Mazen A. Hanna, MDi
Bouke P.C. Hazenberg, MD, PhDj Arnt V. Kristen, MDk
Raymond Y. Kwong, MD, MPHa Mathew S. Maurer, MDc Giampaolo Merlini, MDl,l1 Edward J. Miller, MD, PhDm James C. Moon, MDf Venkatesh L. Murthy, MD, PhDn
C. Cristina Quarta, MD, PhDf Claudio Rapezzi, MDo Frederick L. Ruberg, MDp Sanjiv J. Shah, MDq Riemer H.J.A. Slart, MDh Hein J. Verberne, MD, PhDr
Jamieson M. Bourque, MD, MHS, FASNC (Co-Chair)s | a Cardiac Amyloidosis Program, Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. bDepartment of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan. cColumbia University Medical Center/New York Presbyterian Hospital, Columbia University, NY, USA. dDivision of Hematology, Division of Cardiovascular Diseases, and Department of Radiology, Division of N

FAQs

What problem does Part 2 of this expert consensus address?

It addresses the lack of standardized diagnostic criteria and the appropriate utilization of imaging in cardiac amyloidosis.

Who developed the recommendations in Part 2?

An international panel of experts from multiple societies, including ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI.

Which imaging modalities does the document provide utilization guidance for?

It covers echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging for evaluating patients with known or suspected cardiac amyloidosis.

Oct 2, 2026

Uploaded by dbqoiu